Glaukos iStent technology is the number one minimally invasive glaucoma surgery (MIGS) platform worldwide,1 prioritising safe and effective outcomes that are comparable to cataract surgery alone.
The newest of its technologies, iStent infinite, carries on the legacy of excellence established by iStent devices over the past 20 years. It’s backed by a robust, diverse, and long-term body of clinical evidence providing:
- Sustained intraocular pressure and topical medication reduction,2
- Proven safety with a genuine tissue sparing device,3
- Proven protection against visual field loss,4
- Significant and durable quality of life improvements,5 and
- A 72% reduction in the number of patients with severe ocular surface disease symptoms.6
Visit: glaukos.net.au
References
- Based on units sold.
- Hengerer FH, Auffarth GU, Conrad-Hengerer I. 7-year efficacy and safety of iStent inject trabecular micro-bypass in combined and standalone usage. Adv Ther. 2024;41:1481-1495. doi: 10.1007/s12325-024-02788-y.
- Sarkisian SR Jr, Grover DS, Navratil T, et al. Effectiveness and safety of iStent infinite trabecular micro-bypass for uncontrolled glaucoma. J Glaucoma. 2023;32(1):9-18. doi: 10.1097/IJG.0000000000002141.
- Gillmann K, Hornbeak DM. Rates of visual field change and functional progression in glaucoma following trabecular microbypass implantation of iStent technologies: a meta-analysis. BMJ Open Ophthalmol. 2024;9:e001575. doi: 10.1136/bmjophth-2023-001575.
- Samuelson TW, Singh IP, Katz LJ, et al. Quality of life in primary open-angle glaucoma and cataract: an analysis of VFQ-25 and OSDI from the iStent inject pivotal trial. Am J Ophthalmol. 2021;229:220-229. doi: 10.1016/j.ajo.2021.03.007.
- Schweitzer JA, Hauser WH, Berdahl JP, et al. Prospective interventional cohort study of ocular surface disease changes in eyes after trabecular micro-bypass stent(s) implantation (iStent or iStent inject) with phacoemulsification. Ophthalmol Ther. 2020;9(4):941-953. doi: 10.1007/s40123-020-00290-6.
